EAU 2004 Guidelines on Assessment, Therapy and Follow-Up of Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction (BPH Guidelines)

de la Rosette, 2001, EAU guidelines on benign prostatic hyperplasia (BPH), Eur Urol., 40, 256, 10.1159/000049784 Jacobsen, 1997, Natural history of prostatism: risk factors for acute urinary retention, J Urol., 158, 481, 10.1016/S0022-5347(01)64508-7 Meigs, 1999, Incidence rates and risk factors for acute urinary retention: the Health Professional Follow up Study, J Urol., 162, 376, 10.1016/S0022-5347(05)68563-1 McConnell, 1998, The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia, New Engl J Med, 338, 557, 10.1056/NEJM199802263380901 Roehrborn, 1999, Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rates: results of a four-year, randomised trial comparing finasteride versus placebo, Urology, 54, 662, 10.1016/S0090-4295(99)00232-0 Anderson, 2001, The progression of benign prostatic hyperplasia: examining the evidence and determining the risk, Eur Urol., 39, 390, 10.1159/000052475 Gerber, 1997, Serum creatinine measurement in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia, Urology, 49, 697, 10.1016/S0090-4295(97)00069-1 McConnell, 2003, The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia, N Engl J Med, 349, 2387, 10.1056/NEJMoa030656 Griffiths, 1997, Standardization of terminology of lower urinary tract function: pressure-flow studies of voiding, urethral resistance and urethral obstruction. International Continence Subcommittee on Standardization of Terminology of Pressure-Flow Studies, Neurourol Urodyn., 16, 1, 10.1002/(SICI)1520-6777(1997)16:1<1::AID-NAU1>3.0.CO;2-I Watanabe, 1998, New concept of BPH: PCAR theory, Prostate, 37, 116, 10.1002/(SICI)1097-0045(19981001)37:2<116::AID-PROS8>3.0.CO;2-E Gisholf, 2000, Analysis and reliability of data from 24-hour frequency-volume charts in men with lower urinary tract symptoms due to benign prostatic hyperplasia, Eur Urol., 38, 45, 10.1159/000020251 Kirby, 2000, The natural history of benign prostatic hyperplasia: what have we learned in the last decade?, Urology, 56, 3, 10.1016/S0090-4295(00)00747-0 Brown, 2004, Could self-management challenge pharmacotherapy as a long-term treatment for uncomplicated lower urinary tract symptoms, Curr Opin Urol., 14, 7, 10.1097/00042307-200401000-00002 Marberger, 2004, Optimizing the medical management of benign prostatic hyperplasia, Eur Urol., 45, 411, 10.1016/j.eururo.2003.10.016 Roehrborn, 2002, Efficacy and safety of a dual inhibitor of 5-alpha-reductase type 1 and 2 (dutasteride) in men with benign prostatic hyperplasia, Urology, 60, 434, 10.1016/S0090-4295(02)01905-2 Lam, 2003, Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up, Urology, 61, 354, 10.1016/S0090-4295(02)02149-0 Chapple, 2001, Alpha adrenoreceptor antagonists in the year 2000: is there anything new?, Curr Opin Urol., 11, 9, 10.1097/00042307-200101000-00002 McNeil, 1999, Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective placebo-controlled study, BJU Int., 84, 622, 10.1046/j.1464-410x.1999.00277.x Dreikorn, 2002, The role of phytotherapy in treating lower urinary tract symptoms and benign prostatic hyperplasia, World J Urol., 19, 426, 10.1007/s00345-002-0247-6 Debruyne, 2002, Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomised international study, Eur Urol., 41, 497, 10.1016/S0302-2838(02)00066-0 Lepor, 1996, The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia, N Engl J Med, 335, 533, 10.1056/NEJM199608223350801 Debruyne, 1998, Sustained-release alfuzosin, finasteride and the combination of both in the treatment of BPH, European ALFIN study group Eur Urol., 34, 169, 10.1159/000019706 Kirby, 2003, Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial, Urology, 61, 119, 10.1016/S0090-4295(02)02114-3 Madersbacher, 1999, Is transurethral resection of the prostate still justified?, Br J Urol., 83, 227, 10.1046/j.1464-410x.1999.00908.x Yang, 2001, Transurethral incision compared with transurethral resection of the prostate for bladder outlet obstruction: a systematic review and meta-analysis of randomised controlled trials, J Urol., 165, 1526, 10.1016/S0022-5347(05)66342-2 Hammadeh, 2003, Transurethral electrovaporisation of the prostate (TUVP) is effective, safe and durable, Prostate Cancer Prostatic Dis., 6, 121, 10.1038/sj.pcan.4500654 Costello, 1999, Side-firing neodymium:YAG laser prostatectomy, Eur Urol., 35, 138, 10.1159/000019834 Schatzl, 1997, The early postoperative morbidity of transurethral resection of the prostate and of four minimally invasive treatment alternatives, J Urol., 158, 105, 10.1097/00005392-199707000-00029 Muschter, 1999, Interstitial laser therapy of benign prostatic hyperplasia, Eur Urol., 35, 147, 10.1159/000019835 Tooher, 2004, A systematic review of holmium laser prostatectomy for benign prostatic hyperplasia, J Urol., 171, 1773, 10.1097/01.ju.0000113494.03668.6d de Wildt, 2000, Clinical results of microwave thermotherapy for benign prostatic hyperplasia, J Endourol., 14, 651, 10.1089/end.2000.14.651 de la Rosette, 2003, Transurethral microwave thermotherapy: the gold standard for minimally invasive therapies for patients with benign prostatic hyperplasia?, J Endourol., 17, 245, 10.1089/089277903765444393 AUA Practice Guidelines Committee, 2003, AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations, J Urol, 170, 530, 10.1097/01.ju.0000078083.38675.79 Bruskewitz, 1998, A prospective randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia, J Urol., 159, 1588, 10.1097/00005392-199805000-00048 Zlotta, 2003, Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers, Eur Urol., 44, 89, 10.1016/S0302-2838(03)00218-5